MARKET WIREReuters • 3h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
Why UPC Stock dropped -20.21% Today — RQD Quant Desk Flash
$1.54 -20.21% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.48
Universe Pharmaceuticals Inc. (Class A) (UPC) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $7.7M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.48 (-3.83%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-11% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for UPC)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (33/100 Composite)
🔍 WHY UPC SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+9/20 pts (27% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 35.3% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (24% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$4.15-5.3% Next Q
41
Q2 (-2Q)Grade E$3.93+10.4% Next Q
38
Q3 (-1Q)Grade E$4.34-64.5% Next Q
36
CurrentGrade E$1.54-8.9% Hist 90D α
33
Trajectory: D (41) → E (33)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a UPC Turnaround Squeeze
While UPC currently carries a cautious 33/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.22) and Max Pain ($1.62) forces dealer call-delta covering toward $18.86.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $UPC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “UPC Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why UPC Stock dropped -20.21% Today — RQD Quant Desk Flash
Universe Pharmaceuticals Inc. (Class A) (UPC) dropped -20.21% to $1.54, trading at 2% of its 52-week range ($1.45 – $17.96). Stretched risk/reward at current multiples (35% profit margin) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($1.45 – $17.96) with RSI-14 at 22.2 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.54 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 35.3% gross margin and $0 annual free cash flow.
Live UPC Headlines & Catalysts
MARKET WIRECNBC • 5h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 5h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 7h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 8h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 9h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 9h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 10h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring UPC)
- ✓Walkthrough of UPC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
UPC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -52.32%▼ SUPPORT BREAKDOWN
2026-10-30O $1.50H $1.67L $1.45C $1.54VOL 548.8K
RES: $4.26SUP: $3.90SMA50: $4.22SMA200: $3.82
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
UPC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -22.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on UPC today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for UPC. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for UPC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (UPC)
Health Care Rank #884 of 1016
⚔️ CURX vs UPC Full Matrix →
1. Head-to-Head Health Care Peer Comparison (UPC vs. CURX, KPRX, TCRT, MTVA)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Universe Pharmaceuticals Inc. (Class A) (UPC) ranks #884 by composite RQD confidence (33/100, grade E) and #917 by equity capitalization ($7.7M). Within this direct 5-issuer industry benchmark cohort, UPC leads on earnings valuation at N/A trailing P/E, while CURX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. MTVA currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with UPC at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| UPC
ACTIVE
Universe Pharmaceuticals Inc. (Class A) | E | 33/100 | — | 35.3% | — | -20.21% | $7.7M | Benchmark Subject |
| CURX Curanex Pharmaceuticals Inc | D- | 37/100 | — | — | -35.0% | -0.20% | $7.7M | /curx-vs-upc → |
| KPRX Kiora Pharmaceuticals Inc. | E | 32/100 | — | — | -35.0% | -25.42% | $7.8M | /kprx-vs-upc → |
| TCRT Alaunos Therapeutics Inc. | E | 31/100 | — | — | -35.0% | -11.27% | $7.8M | /tcrt-vs-upc → |
| MTVA MetaVia Inc. | D | 47/100 | — | — | -35.0% | +4.39% | $7.8M | /mtva-vs-upc → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-09-30 • CIK 0001809616In its most recent audited fiscal period (FY2025, filed 2025-09-30), Universe Pharmaceuticals Inc. (Class A) (UPC) reported GAAP revenue of $17.86B (-22.4% vs. FY2024 revenue of $23.02B , and -44.7% cumulative change since FY2023) , GAAP net income of -$3.67B, operating cash flow of -$5.05B, and free cash flow of -$5.32B (+45.2% YoY). On the balance sheet, UPC closed FY2025 with $69.30B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-09-30 | $17.86B | -$3.67B | -$5.05B | -$5.32B | $69.30B | — |
| FY2024 (FY) | 2024-09-30 | $23.02B | -$8.73B | -$9.51B | -$9.72B | — | — |
| FY2023 (FY) | 2023-09-30 | $32.31B | -$6.58B | $1.12B | $1.12B | — | — |
3. UPC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs UPC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Universe Pharmaceuticals Inc. (Class A) (NASDAQ: UPC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $1.54 (-20.21% 1D, market cap $7.7M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, UPC ranks #884 in composite RQD confidence.
How does UPC compare to CURX and KPRX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), UPC carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of 35.3%, and ROIC of —. By comparison, CURX (Curanex Pharmaceuticals Inc) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $7.7M) and KPRX (Kiora Pharmaceuticals Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $7.8M). Among the 5-stock peer group, UPC leads on earnings multiple (N/A) while CURX leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for UPC?
Per UPC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-09-30, CIK 0001809616), Universe Pharmaceuticals Inc. (Class A) generated $17.86B in revenue (-22.4% YoY), -$3.67B in net income, and -$5.32B in free cash flow against $69.30B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is UPC trading relative to its 50-day, 200-day, and 52-week technical levels?
UPC last traded at $1.54 (-20.21% on volume of 980,963 shares), positioning the stock -63.51% below its 50-day simple moving average ($4.22) and -59.69% below its 200-day simple moving average ($3.82). Across its 52-week range of $1.45 to $17.96, UPC sits at the 0.5% percentile with a 14-day RSI of 22.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.35 to $1.73).
UPC Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is UPC stock moving today?
Why UPC Stock dropped -20.21% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (35% profit margin) under elevated 10-year interest-rate pressure.